Seattle Genetics Inc. (SGEN)

Oncology Corporate Profile

Stock Performance

38.0700
-1.0100

3 Month Stock History Chart

HQ Location

21823 30th Drive SE
Bothell, WA 98021

Company Description

Seattle Genetics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.

Website: http://www.seattlegenetics.com

Brand Generic Indication
Abraxane®paclitaxel nanoparticle albumin-boundAbraxane® is a microtubule inhibitor indicated for the treatment of:Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

•Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

•Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.
Adcetris®brentuximab vedotinAdcetris® is a CD30-directed antibody-drug conjugate indicated for treatment of patients with:

•Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

•Classical HL at high risk of relapse or progression as post-auto-HSCT consolidation.

•Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen (1.3). Accelerated approval was granted for the sALCL indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
brentuximab vedotinantibody drug conjugate (anti-CD30)2nd line Hodgkin's LymphomaIIITakeda
brentuximab vedotinantibody drug conjugate (anti-CD30)Cutaneous T-cell Lymphoma (CTCL)III
brentuximab vedotinantibody drug conjugate (anti-CD30)Hodgkin's LymphomaIII
Denintuzumab mafodotin / SGN-CD19Aantibody drug conjugate (anti-CD19)1st line diffuse large B-cell lymphoma (DLBCL)II
Denintuzumab mafodotin / SGN-CD19Aantibody drug conjugate (anti-CD19)2nd line diffuse large B-cell lymphoma (DLBCL)II
brentuximab vedotinantibody drug conjugate (anti-CD30)CD30-expressing mature T-cell Lymphoma (MTCL)II
SGN-CD19Aantibody drug conjugate (anti-CD19)Diffuse large B-cell Lymphoma (DLBCL)II
Enfortumab vedotin / ASG-22MEantibody drug conjugate (anti-Nectin-4)Metastatic Urothelial cancerIIAstellas
brentuximab vedotinantibody drug conjugate (anti-CD30)Relapsed CD30-expressing diffuse large B-cell lymphoma (DLBCL)II
brentuximab vedotinantibody drug conjugate (anti-CD30)Relapsed Non-Hodgkin's Lymphoma (NHL)II
SGN-CD19Aantibody drug conjugate (anti-CD19)Acute Lymphocytic Leukemia (ALL)I
SGN-CD19Bantibody drug conjugate (anti-CD123)Acute Myelogenous Leukemia (AML)I
SGN-CD19Bantibody drug conjugate (anti-CD19)B-cell Non-Hodgkin's Lymphoma (NHL)I
ASG-15MEantibody drug conjugate (ADC)Bladder cancerIAstellas
SGN-LIV1Aantibody drug conjugate (ADC)Breast cancerI
SGN-LIV1Aantibody-drug conjugate (ADC)Breast cancerI
SGN-CD352Aantibody drug conjugate (anti-CD30)Multiple MyelomaI
SGN-CD48Aantibody drug conjugate (anti-CD30)Multiple MyelomaI
SGN-CD70Aantibody drug conjugate (anti-CD70)Non-Hodgkin's Lymphoma (NHL)I
SGN-CD19Aantibody drug conjugate (anti-CD19)Non-Hodgkin's Lymphoma (NHL)I
SEA-CD40CD40 inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.seattlegenetics.com

Recent News Headlines

Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma

11/8/2016 05:27 pm

(BioMed Reports) Nov 8, 2016 - ECHELON-2 trial represents key component of late-stage clinical development strategy to establish Adcetris as foundation of care for CD30-expressing lymphomas; data from ECHELON-2 phase 3 trial expected in 2017 to 2018 timeframe.

ACCC President Jennie R. Crews Named Medical Director for Seattle Cancer Care Alliance

10/17/2016 04:31 pm

(ACCC) Oct 14, 2016 - The Association of Community Cancer Centers (ACCC) congratulates current President Jennie R. Crews, MD, MMM, FACP, on her new position as medical director for Seattle Cancer Care Alliance (SCCA).

Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress

10/7/2016 04:00 pm

(Yahoo! Finance) Oct 7, 2016 - Seattle Genetics, Inc. and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO) Congress being held October 7-11, 2016 in Copenhagen, Denmark.

140 Cancer Patients In Seattle Area Warned Of TB Risk From Health Worker

8/17/2016 04:24 pm

(Seattle Times) Aug 16, 2016 - About 140 cancer patients may have been exposed to tuberculosis by a health-care worker who was diagnosed with an active case of the disease, officials with the University of Washington Medical Center and the Seattle Cancer Care Alliance said Tuesday.

Takeda and Seattle Genetics Announce Positive Data From Trial For Cutaneous T-Cell Lymphoma

8/1/2016 04:52 pm

(European Pharmaceutical Review) Aug 1, 2016 - Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4).

Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma

8/1/2016 12:16 pm

(Takeda) Aug 1, 2016 - Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. today announced that the Phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL) met its primary endpoint, demonstrating a highly statistically significant improvement in the rate of objective response lasting at least four months (ORR4).

Seattle Cancer Care Alliance Settles Oxycodone Investigation for $250K

7/8/2016 04:15 pm

(Puget Sound Business Journal) July 7, 2016 - The Seattle Cancer Care Alliance has agreed to pay $250,000 to settle a U.S. Justice Department investigation relating to the loss of more than 96,000 pills between 2011 and 2013.

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

6/13/2016 05:00 pm

(The Business Journals) June 11, 2016 - Phase 1 clinical data featured in press program and oral presentation demonstrate 76 percent objective response rate, including a 41 percent complete remission rate, in newly diagnosed AML patients treated with 33A combination therapy; data support recently initiated phase 3 CASCADE study evaluating 33A in combination with hypomethylating agents in AML patients.

Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in Metastatic Urothelial Cancer at ASCO Annual Meeting

6/6/2016 10:35 pm

(TMCnet.com) June 6, 2016 - Seattle Genetics, Inc. and Astellas Pharma Inc. today presented first clinical data for ASG-15ME and enfortumab vedotin (ASG-22ME) at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting being held June 3-7, 2016, in Chicago, IL.

Seattle Children's T-Cell Immunotherapy Clinical Trial for Children With Relapsed Leukemia Shows 93% Complete Remission Rate

6/3/2016 06:28 pm

(Seattle Children's) June 2, 2016 - Seattle Children's announced today that 39 of 42 patients treated in a Phase 1 clinical trial using genetically reprogrammed T cells to treat relapsed or refractory acute lymphoblastic leukemia (ALL) have achieved complete remission, showing no detectable leukemia cells in the most sensitive tests.

Biosimilar Shows Comparable Efficacy, Safety to Trastuzumab in Advanced Breast Cancer

6/3/2016 02:01 pm

(ASCO Annual Meeting) June 3, 2016 - A biosimilar trastuzumab antibody (MYL-­1401O) is comparable in efficacy and safety to the FDA-approved targeted breast cancer drug trastuzumab (Herceptin) in women with HER2-­positive advanced breast cancer, according to a randomized phase III study.

Seattle Genetics Initiates Pivotal Phase 3 Trial of Vadastuximab Talirine (SGN-CD33A) for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

5/25/2016 04:11 pm

(Seattle Genetics) May 25, 2016 - Seattle Genetics, Inc. today announced initiation of a pivotal phase 3 clinical trial, called CASCADE, evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) or decitabine (Dacogen) in older patients with newly diagnosed acute myeloid leukemia (AML).

Seattle Genetics Highlights Novel Antibody-Drug Conjugate (ADC) Technology Advances at the American Association for Cancer Research (AACR) Annual Meeting

4/18/2016 04:23 pm

(Morningstar) Apr 17, 2016 - Innovative research demonstrates Seattle Genetics’ leadership in empowered antibodies.

FDA to Review Bristol-Myers’s Opdivo for Hodgkin Lymphoma

4/14/2016 12:03 pm

(Morningstar/Dow Jones Newswires) Apr 14, 2016 - The U.S. Food and Drug Administration has accepted Bristol-Myers Squibb Co.’s supplemental biologics license application to expand the use of its cancer drug Opdivo to patients who are facing difficult-to-treat variations of Hodgkin lymphoma, the pharmaceutical company said Thursday.

Specific Gene In The Tumor Determines The Effectiveness Of Cancer Treatment

4/14/2016 11:01 am

(MedUni Vienna [Austria]) Apr 14, 2016 - Mutations in the TP53 gene can have harmful consequences.

How Medicare Drug Plans Hope To Follow Private Sector Lead

3/18/2016 10:02 am

(Kaiser Health News) Mar 18, 2016 - Aetna and Cigna inked deals in early February with drugmaker Novartis that offer the insurers rebates tied to how well a pricey new heart failure drug works to cut hospitalizations and deaths.

Provectus Biopharmaceuticals Initiating Phase 1 Study of PV-10 in Neuroendocrine Tumors Metastatic to Liver

2/29/2016 12:00 pm

(StreetInsider) Feb 29, 2016 - Provectus Biopharmaceuticals, Inc. today announced that it is initiating a protocol titled, “A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products.”

Seattle Genetics Initiates Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma

2/25/2016 05:47 pm

(Yahoo! Finance) Feb 25, 2016 - Seattle Genetics, Inc. today announced initiation of a phase 1 clinical trial of SGN-CD19B for relapsed or refractory patients with two subtypes of B-cell non-Hodgkin lymphoma (NHL): diffuse large B-cell lymphoma (DLBCL) and grade 3 follicular lymphoma.

Juno Therapeutics, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center Announce New Immuno-oncology Clinical Trials Unit

2/24/2016 05:48 pm

(Yahoo! Finance) Feb 24, 2016 - Juno Therapeutics, Inc., a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and Fred Hutchinson Cancer Research Center (Fred Hutch) today announced the creation of a new, best-in-class clinical trials unit (CTU) dedicated to immuno-oncology.

Seattle Genetics Initiates Phase 1/2 Trial of Vadastuximab Talirine (SGN-CD33A) Combination Therapy for Patients with Untreated Myelodysplastic Syndrome (MDS)

2/22/2016 05:42 pm

(Morningstar) Feb 22, 2016 - Seattle Genetics, Inc. today announced initiation of a phase 1/2 clinical trial of vadastuximab talirine (SGN-CD33A; 33A) in combination with azacitidine (Vidaza) in patients with previously untreated myelodysplastic syndrome (MDS).

FDA Gives Ocrelizumab Breakthrough Designation For PPMS: Roche

2/17/2016 12:03 pm

(Reuters) Feb 17, 2016 - The U.S. Food and Drug Administration has granted breakthrough therapy designation for ocrelizumab (OCREVUS) for treating people with primary progressive multiple sclerosis (PPMS), Swiss drugmaker Roche said on Wednesday.

New Global Initiative for Breast Cancer Has Roots in Seattle

2/5/2016 06:11 pm

(Seattle Cancer Care Alliance) Feb 3, 2016 - World Cancer Day—Thursday, Feb. 4, 2016—is the web launch of a new global campaign to reduce disparities in breast cancer outcomes for 2.5 million women by 2025.

Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin) Collaboration with Takeda

2/4/2016 06:14 pm

(StreetInsider) Feb 4, 2016 - Seattle Genetics, Inc., today announced that it will receive a one-time $20 million milestone payment under its ADCETRIS (brentuximab vedotin) collaboration with Takeda Pharmaceutical Company Limited (Takeda).

Smoking Lowers Breast Cancer Survival, Study Finds

1/27/2016 07:02 am

(Philadelphia Inquirer/HealthDay News) Jan 26, 2016 - Women diagnosed with breast cancer who continue to smoke cigarettes are less likely to survive than those who never smoked or those who quit, new research finds.

Immune System Takes Long Time To Recover After Breast Cancer Chemo

1/26/2016 11:02 am

(Medical News Today) Jan 26, 2016 - New research that looks at the long-term effects of chemotherapy on breast cancer survivors finds it weakens parts of the immune system for at least 9 months after treatment. This could leave patients with insufficient resilience to common infections, such as pneumonia and tetanus, even if they were immunized previously, say the researchers.

Eisai Files Kidney Cancer Drug In Europe

1/12/2016 12:00 pm

(PharmaTimes [UK]) Jan 12, 2016 - Eisai has submitted an application to market its oncology drug lenvatinib for the treatment of patients with renal cell carcinoma.

Gritstone Oncology Enters Into Exclusive Licensing Agreement and Collaboration with Memorial Sloan Kettering Cancer Center

1/12/2016 11:05 am

(WDRB 41 Louisville News) Jan 12, 2016 - Agreement will support discovery and development of personalized cancer immunotherapies.

Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement

1/12/2016 11:05 am

(Yahoo! Finance) Jan 11, 2016 - Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.

Forma Therapeutics Achieves An Additional Major Objective In Collaboration With Celgene Corporation To Advance Innovative Protein Homeostasis Drugs

1/12/2016 11:05 am

(FORMA) Jan 12, 2016 - FORMA Therapeutics announced today that it has successfully met a third objective under its strategic collaboration agreement with Celgene Corporation, triggering an undisclosed payment from Celgene.

Independence Blue Cross to Cover Whole Genome Sequencing

1/12/2016 11:05 am

(Philadelphia Business Journal) Updated Jan 12, 2016 - Independence Blue Cross entered into an agreement with NantHealth to cover next-generation whole genome sequencing for a variety of cancers.

Human Longevity, Inc. to Offer Oncology Products Including Comprehensive Whole Germline, Tumor Genome and Whole Cancer Exome Products

1/12/2016 11:05 am

(HLI) Jan 12, 2016 - Human Longevity, Inc., the genomics-based, technology-driven company, announced today its oncology genomics program, including the development of comprehensive whole germline and tumor genome analysis, as well as tumor and germline exome analysis products.

For Cancer Survivors, Expenses Keep Mounting

1/12/2016 11:05 am

(U.S. News & World Report/HealthDay News) Jan 12, 2016 - A cancer diagnosis is costly, and new research suggests that it remains costly even after the disease has been treated.

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement

1/12/2016 11:04 am

(ACP/Annals of Internal Medicine) Jan 12, 2016 - Update of the 2009 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for breast cancer.

New Analyses Confirms Biennial Mammography Starting At Age 50 Optimal For Average Women

1/12/2016 11:04 am

(GUMC) Jan 11, 2016 - Unanimous finding of six research teams on breast cancer screening provided to USPSTF.

Susan G. Komen®: Women and Health Care Providers Should Have the Final Say on Mammogram Schedules

1/12/2016 11:04 am

(Yahoo! Finance) Jan 11, 2016 - Komen renews concern over Task Force proposal to raise routine mammography age.

Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program

1/12/2016 11:04 am

(Merck) Jan 11, 2016 - Acquisition grows Merck’s oncology pre-clinical pipeline with novel IDO1 and TDO inhibitors.

BioLineRx Announces Collaboration with MSD to Investigate the Combination of KEYTRUDA (pembrolizumab) and BL-8040 in Pancreatic Cancer

1/12/2016 11:04 am

(BioLineRx ) Jan 12, 2016 - BioLineRx Ltd. today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx's BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with metastatic pancreatic cancer.

Federal Panel Finalizes Mammogram Advice That Stirred Controversy

1/12/2016 06:05 am

(NPR/Shots blog) Jan 11, 2016 - After the public had a chance to comment, the influential U.S. Preventive Services Task Force has finalized their latest breast cancer screening recommendations, reiterating that women ages 50-74 ought to receive a screening mammogram every two years.

New Breast Cancer Screening Guidelines At Odds With Congress

1/12/2016 06:04 am

(Washington Post) Jan 11, 2016 - Congress has sided with proponents of earlier screening.

Novartis Signs $170 Million Immuno-Oncology Pact With Surface

1/11/2016 12:05 pm

(Reuters) Jan 11, 2016 - Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body's immune system fight cancer.

Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hodgkin Lymphoma

12/23/2015 04:36 pm

(Morningstar) Dec 23, 2015 - Seattle Genetics, Inc. and Bristol-Myers Squibb today announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab) for patients with CD30-expressing relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas (NHL), including diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Seattle Genetics Presents Phase 1 Data from Novel Antibody-Drug Conjugate SGN-LIV1A at San Antonio Breast Cancer Symposium

12/10/2015 06:05 pm

(Yahoo! Finance) Dec 10, 2015 - Seattle Genetics, Inc. today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate (ADC) in development for patients with LIV-1-expressing metastatic breast cancer (MBC), at the 38th San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas, December 8-12, 2015.

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015

12/7/2015 10:57 pm

(StreetInsider) Dec 7, 2015 - Seattle Genetics, Inc. today highlighted data presentations evaluating ADCETRIS (brentuximab vedotin) in frontline non-Hodgkin lymphoma at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015.

Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015

12/7/2015 08:08 pm

(Yahoo! Finance) Dec 7, 2015 - Seattle Genetics, Inc. today highlighted several data presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, evaluating ADCETRIS (brentuximab vedotin) as both monotherapy and combination therapy in multiple Hodgkin lymphoma (HL) disease settings.

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 2015

12/7/2015 08:01 pm

(Stockhouse) Dec 7, 2015 - 33A combination therapy and monotherapy demonstrate encouraging anti-leukemic activity in AML; data highlighted in oral presentations; planning 33a phase 3 trial in older AML patients.

Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015

12/6/2015 08:39 pm

(Yahoo! Finance) Dec 6, 2015 - Updated data from phase 1 clinical trials support further clinical evaluation of SGN-CD19A in randomized phase 2 trials: testing novel regimens for frontline and relapsed DLBCL.

Seattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia

11/23/2015 05:39 pm

(Yahoo! Finance) Nov 23, 2015 - Seattle Genetics, Inc. today announced initiation of a phase 1/2 clinical trial of SGN-CD33A (vadastuximab talirine) in patients with relapsed or refractory acute myeloid leukemia (AML).

Seattle Genetics Announces More Than 20 Presentations at ASH 2015 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Plan and Multiple Antibody-Drug Conjugate (ADC) Pipeline Programs

11/6/2015 05:33 pm

(Yahoo! Finance) Nov 6, 2015 - Seattle Genetics, Inc. today announced that a record number of abstracts were accepted for presentation at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015.

Cyrus Ghajar Receives $4.1M Grant to Study Ways to Prevent Metastatic Breast Cancer

6/30/2015 12:01 pm

(Fred Hutch News) June 29, 2015 – Cyrus Ghajar, Ph.D., a metastatic breast cancer researcher at Fred Hutchinson Cancer Research Center, has received a $4.1 million Department of Defense Breast Cancer Research Program (BCRP) “Era of Hope” Scholar Award.

GenomeDx Announces Launch of Decipher GRID™ and Partnership with Sidney Kimmel Cancer Center to Accelerate Innovation in Urologic Cancer Patient Care

5/12/2015 12:00 pm

(GenomeDx) May 12, 2015 - GenomeDx Biosciences today announced the launch of the Decipher® Genomics Resource Information Database (Decipher GRID™), a clinical genomics data sharing program that unites patient registries from leading cancer centers with GenomeDx's full genome profiling platform.